WESTLAKE VILLAGE, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the appointment of Caroline Van Hove as the Company’s first Chief Commercial Officer. Ms. Van Hove will develop, lead and have overall responsibility for Sienna’s commercial strategy and operations. Sienna currently has five clinical-stage programs in development from the Company’s Topical by Design™ and Topical Photoparticle Therapy™ platforms.
“We are delighted to welcome Caroline to Sienna as Chief Commercial Officer,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. “Caroline brings a wealth of senior healthcare experience and an exemplary track record of establishing winning commercial strategies, building highly effective teams and leading international commercial operations for billion-dollar brands, along with a visionary approach to market development and sales-and-marketing excellence. We look forward to her contributions as we work on building exceptional brands and robust market awareness in preparation to commercialize our innovative multi-asset pipeline.”
Ms. Van Hove joins Sienna as a global leader with 20 years of diverse experience in the pharmaceutical, consumer and medical device industry, managing sales and marketing, commercial excellence, public relations and corporate affairs functions. Her global agency and large healthcare company experience spans North America to Europe, Africa, the Middle East to Asia Pacific and Latin America.
Most recently, Ms. Van Hove served as senior vice president of international strategic marketing at Allergan, where she oversaw commercial operations for the medical aesthetics, eye care and specialty care franchises, including portfolio development. Previously, Ms. Van Hove held a series of escalating sales-and-marketing and corporate positions, starting in public relations, supporting the organization through several high-profile crises and issues, acquisitions and company milestones. She managed commercial operations in Europe, Africa and the Middle East, led Allergan’s international medical aesthetics operations, drove many of the company’s key acquisitions and integrations and helped establish a new international operating model for its medical aesthetics, ophthalmology and specialty care business. Ms. Van Hove also served as part of Allergan’s Global Operating & International Leadership Teams. She holds an Executive Master of Business Administration from the Kellogg School of Management at Northwestern University, as well as bachelor’s degrees in journalism from the University of Central Florida and in modern linguistics from the University of Antwerp.
“Sienna presents a unique opportunity to disrupt the biotech industry with distinctly smart science that will put patient safety truly front and center, while also offering a unique pathway for possible solutions in multiple other specialties where needs run high,” said Ms. Van Hove. “I look forward to adding to the team’s expertise, as we work toward delivering a high return for patients, physicians and our shareholders by advancing best-in-class therapies in medical dermatology from development to market.”
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The Company’s objective is to develop an innovative, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies.
For more information, visit the Company’s website at www.SiennaBio.com.
Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to the statements by Sienna’s Chief Executive Officer and Chief Commercial Officer and other statements regarding Sienna’s potential, including its ability to develop and commercialize product candidates in multiple specialties. Such forward-looking statements involve substantial risks and uncertainties that could cause Sienna’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the clinical trial enrollment process, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Sienna’s ability to successfully protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations and the availability or commercial potential of Sienna’s product candidates. Sienna undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see Sienna’s most recent Annual Report on Form 10-K and any subsequent current and periodic reports filed with the Securities and Exchange Commission.
Contact:
Sean Andrews (Investors)
sandrews@siennabio.com
818-629-2244
Crystal Muilenburg (Media)
cmuilenburg@siennabio.com
818-584-1035